Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Not Confirmed
Not Confirmed
08-10 October, 2025
Pharma MES 2025Pharma MES 2025
Not Confirmed
Not Confirmed
10-11 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Industry Trade Show
Not Confirmed
08-10 October, 2025
Pharma MES 2025Pharma MES 2025
Industry Trade Show
Not Confirmed
10-11 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-bridge-the-gap-between-chemistry-and-performance-to-deliver-precise-optimized-micronization-for-complex-apis
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/global-api-micronization-market-set-to-surge-49-by-2030-led-by-specialized-industry-pioneers
21 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-asc47-in-combination-with-semaglutide-demonstrated-up-to-56-2-greater-relative-reduction-in-body-weight-in-participants-with-obesity-compared-to-semaglutide-monotherapy-302562415.html
17 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/17/3151490/0/en/Positive-Phase-3-Results-for-Denifanstat-for-the-Treatment-of-Moderate-to-Severe-Acne-to-be-Presented-at-the-EADV-Congress-2025-by-Partner-Ascletis.html
09 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-ultra-long-acting-subcutaneous-depot-maintenance-formulation-of-small-molecule-glp-1r-agonist-asc30-demonstrated-an-observed-half-life-of-75-days-in-participants-with-obesity-302550420.html
02 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-to-present-28-day-multiple-ascending-dose-study-results-of-oral-small-molecule-glp-1r-agonist-asc30-at-the-61st-european-association-for-the-study-of-diabetes-easd-annual-meeting-302543427.html
27 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-favorable-and-differentiated-pharmacokinetic-profile-of-asc30-oral-once-daily-tablet-in-its-us-phase-ib-multiple-ascending-dose-study-302540456.html
17 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-the-combination-of-asc47-and-asc31-its-dual-glp-1rgipr-peptide-agonist-demonstrated-significantly-greater-weight-loss-compared-to-the-combination-of-asc47-and-tirzepatide-in-an-animal-model-of-obesity-302531465.html
ABOUT THIS PAGE